Oxytocin Modulates Eye Gaze Behavior During Social Processing and Associations With Trait Autism
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Global eye gaze characteristic: differences between oxytocin and placebo treatment
研究概览
简要总结
The main aim of the study is to examine whether the effects of intranasal oxytocin on eye-gaze behavior towards social stimuli are modulated via individual differences in trait autism
详细描述
In this double-blind, within subject, placebo controlled design a total of n = 40 healthy male subjects will receive either 24 IU of oxytocin or placebo (interval between administration > two weeks). 45 minutes after treatment subjects will undergo a total of 7 eye-tracking paradigms examining eye-gaze behavior during social processing: (1) dynamic social-nonsocial visual preference task during which movies of dynamic geometric images (DGI) and dynamic social images (DSI) will be presented; (2) non-biological versus biological motion task; (3) social attention and motivation of sharing enjoyment; (4) preference for emotional faces versus schematic faces (emoticons); (5) shared social attention - shared gaze direction with an actor shifting his attention to different objects; (6) preferred visual scanning of face regions in emotional faces; and, (7) eye gaze in response to empathy eliciting visual stimuli. Autistic and associated traits will be assessed using the Autism Spectrum Quotient (ASQ), Social Responsibilities Scale (SRS) and the Interpersonal Reactivity Index (IRI). Within-subject differences in the effects of oxytocin on social eye gazing behaviour will be related to individual differences in autistic traits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 30 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects without any past or present psychiatric or neurological disorders
排除标准
- •History of brain injury
- •Visual impairments
- •Use of medication
- •Contraindications for oxytocin administration
研究组 & 干预措施
Order of administration: oxytocin - placebo
Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
干预措施: intranasal oxytocin (Drug)
Order of administration: oxytocin - placebo
Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
干预措施: intranasal placebo (Drug)
Order of administration: placebo - oxytocin
Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
干预措施: intranasal oxytocin (Drug)
Order of administration: placebo - oxytocin
Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
干预措施: intranasal placebo (Drug)
结局指标
主要结局
Global eye gaze characteristic: differences between oxytocin and placebo treatment
时间窗: 45-90 minutes after treatment administration
Global eye-gaze patterns will be compared between the administration of oxytocin and placebo
Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment
时间窗: 45-90 minutes after treatment administration
Localized feature-specific eye gaze patterns will be compared between oxytocin and placebo treatment
次要结局
- Global eye gaze characteristic - associations with autism traits(45-90 minutes after treatment administration)
- Feature-specific eye gaze characteristics - associations with trait autism(45-90 minutes after treatment administration)
研究者
Keith Kendrick
Professor
University of Electronic Science and Technology of China
